PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines

Core Insights - PharmAla Biotech Holdings Inc. has launched the Phenesafe AI platform, aimed at developing novel substituted phenethylamine molecules for patenting and further development [1][2] - The company believes that the MDXX class has significant potential for treating various psychiatric and neurological conditions, and the Phenesafe AI platform will enhance their drug discovery capabilities [2][3] Company Overview - PharmAla Biotech is focused on the research, development, and manufacturing of MDXX class molecules, including MDMA, and is the only company providing clinical-grade MDMA for patient treatments outside of clinical trials [4] - The company aims to alleviate the backlog of generic, clinical-grade MDMA for clinical trials and commercial sales while also developing novel drugs within the same class [4] Phenesafe AI Platform - The Phenesafe AI platform combines various tools, including a QSAR model developed with the University of Windsor and specialized AI chemical pathway modeling tools, to facilitate the development and patenting of new molecules [2] - The platform is designed to streamline the drug discovery process by identifying targets, assessing synthesis feasibility, and focusing on safety and intended function [3] Research and Development Focus - PharmAla's R&D unit has completed proof-of-concept research into several intellectual property families, including its lead drug candidate ALA-002 [4] - The company emphasizes the importance of regulatory relationships and safety pharmacology in achieving success in the psychedelics industry [5]